The effect of dipeptidyl peptidase-4 (DPP4) inhibitors on the development of cardiovascular disease in diabetic patients.

A project submitted to the council of College of Medicine / University of Diyala in partial fulfillment of the requirement for the degree of bachelor.

DONE BY:

ZIYAD EYAD

SUPERVISED BY:

DR. QUTAIBA GHANIM

2022 A.D **1443 A.H**

ACKNOWLEDGMENT

In the name of ALLAH, the most merciful, the most compassionate.

We would like to thank God for his mercy and grace, and we hope that God will accept this work with good acceptance.

We would like to express our sincere gratitude, thanks and appreciation for our supervisor Dr.QUTAIBA GHANIM, for his valuable and helpful advice and suggestion he provided and all his efforts made to complete this research.

INTRODUCTION

T2DM is a well-studied chronic metabolic disease that after left untreated or insufficiently managed can cause serious microvascular and macrovascular complications. The blood glucose-lowering agents akin to metformin, medication derivatives, and endocrine all can improve glycemic management in patients with T2DM, but these agents have restricted or no impact on the associated CV risk factors attendant T2DM also as dyslipidemia, hypertension, and obesity. Treatment with every antidiabetic drug derivatives and internal secretion has been regarding weight gain, which might diminish any positive effects on tube endpoints, and thiazolidinediones have even been related to an enlarged risk of CVD. Thus, there' a need to form positive that any new medication for T2DM isn't regarding a harmful impact on CV outcomes. aldose physiological state is achieved by a elaborate interaction of hormones, primarily endocrine, glucagon, amylin, and incretins. Incretins are secreted from canal in response to food intake and have several general effects, also as glucose-dependent stimulation of internal secretion secretion by secreter beta-cells. two incretins are identified: glucagon-like amide-1 (GLP-1), derived from the L-cells of the distal gut and massive bowel, and glucose-dependent insulinotropic peptide (GIP), derived from the K-cells of the proximal very little intestine. further effects of GLP-1 embrace suppression of postprandial internal secretion secretion from secreter alpha-cells, fastness of gastric emptying, and improvement of repletion at a complex body part level resulting in reduced food intake. GLP-1 and GIP are glucose-lowering agents which will interfere with postprandial hyperglycemia, that has been regarding CV complications. G-protein-coupled receptors for GLP-1 are gift in several tissues including.cardiac myocytes, but their physiological action at these different sites remains unknown The macromolecule dipeptidyl peptidase- (DPP-) 4, collectively referred to as ADA complexing protein 2, degrades every GLP-1 and GIP to their inactive metabolites. medication competitive inhibition of DPP-4 will increase the halflife and bioavailability of active incretins, enhancing their physiological effect. Currently procurable DPP-4 inhibitors embrace sitagliptin, saxagliptin, linagliptin, alogliptin, and vildagliptin. The initial four are approved among the USA and throughout a ton of of the world for the treatment of T2DM; vildagliptin has been approved to be utilized in Europe and Latin America. completely different members of this class are in clinical trial clinical trial clinical trials and embody dutogliptin and gemigliptin. With daily doses ranging from 100 mg for sitagliptin to 5 mg for saxagliptin and linagliptin, the drugs are all similar in their effectivity in lowering HbA1c levels, safety profiles, and patient tolerance. DPP-4 inhibitors lead to a mean decrease in A1C ranging between 0.5% and 1%. during this review, we have a tendency to are getting to concentrate on the protective CV effects of DPP-4 inhibitors. management for 24 weeks. The results showed each} pulse and beat force per unit space attended decrease throughout the study in every treatment cluster compared to placebo. The decrease in heartbeat pressure level in patients receiving 100 mg vildagliptin daily was significantly larger than that in patients receiving placebo. further studies can have to be compelled to be done to elucidate the results of DPP-4 inhibition on hypertension.

The classic mechanism of DPP4 inhibitors.

DPP4 is an enzyme that is widely distributed throughout the body and highly expressed on endothelial cells. It binds to the intravascular portion of vascular endothelial cells and also exists in a soluble circulating form. It is a serine protease that cleaves peptides between amino acids 2 and 3 of the N-terminus, particularly when the second amino acid is alanine or proline. GLP19-36, which is largely inactive. The inactivation of GLP1 by DPP4 is rapid and extensive, and it has been estimated that the increase in GLP1 concentration in peripheral venous plasma accounts for less than 10% of the increase in portal concentration, with the consequence that after inhibition of DPP4 much higher Levels of GLP1 are observed in the portal vein rather than in the peripheral plasma as shown with vildagliptin in pigs. Holst and Deacon first showed the importance of the removal of the two N-terminal amino acids in GLP1 by DPP4 for the rapid inactivation of GLP1 in vivo and also showed that an inhibitor of DPP4 (valine pyrrolidide) prevented the inactivation of exogenously infused GLP1 and increased its insulinotropic effect in pigs.All DPP4 inhibitors used in clinical practice have been shown to produce robust and long-lasting inhibition of plasma DPP4 activity. Some of the DPP4 inhibitors have also been shown to increase GLP1 levels (intact) after food intake. In addition, it has been shown that intact GLP1 levels not only increase after food intake, but also during the 24-hour period of elevated fasting levels.

Based on these findings, the classical mechanism for DPP4 inhibition is that due to the prevention of GLP1 inactivation in the peripheral circulation, the increase in circulating intact GLP1 leads to stimulated insulin secretion and inhibited insulin secretion of glucagon, resulting in increased glucose utilization leads and decreased hepatic glucose. Production that lowers HbA1c by lowering postprandial and fasting glucose. However, several recent findings, primarily in acute studies in non-diabetic rodents, have revealed that the classic mechanism of DPP4 inhibition to lower glucose levels by inhibiting the enzyme in peripheral plasma and thus increasing circulating levels of intact GLP1 may not be the full force explains this approach and that tissue DPP4 and/or neuronal effects may also contribute. This Perspective in Diabetes summarizes these nonclassical effects to illustrate the mechanistic complexity of this glucose-lowering strategy in type 2 diabetes.



Figure 1 (mechanism of DDP-4 inhibitors)

The effects of DPP-4 inhibitors on CVS.



Figure 2 (CVS effects of DDP-4i)

ADA indicates adenosine deaminase; ANP, atrial natriuretic peptide; ApoB, apolipoprotein B; CM, chylomicrons; ERK, extracellular signal-regulated kinase; FFAs, free fatty acids; GLP-1, glucagon-like peptide-1; GIP, gastric inhibitory peptide; JNK, c-Jun N-terminal kinase; NFκB, nuclear factor-κB; sDPP4, soluble DPP4; and VLDL, very-low-density lipoprotein

hypertension.

T2D and hypertension frequently coexist in the same patient. Several clinical studies have been conducted on the potential effects of DPP4 inhibitors on CV risk factors including hypertension. There are insufficient data to determine whether effects are directly associated with DPP4 inhibition or mediated by modulation of incretin hormone physiology. demonstrated that inhibition of DPP4 in the microcirculation relaxes nitric oxide-mediated vascular tone causing peripheral vasodilation and decreased peripheral vascular resistance. Researchers have proposed that the effect of this class of drugs on vascular relaxation may promote better blood pressure control .However, in most DPP4 studies in humans, no consistent effect on blood pressure has been demonstrated. In a small study. found that sitagliptin treatment in non-diabetic patients was associated with a 23 mmHg reduction in systolic blood pressure as assessed by 24-hour ambulatory monitoring. raised the possibility of an undesirable hemodynamic interaction between DPP4 inhibition and high-dose ACE inhibition in humans. When sitagliptin was used concomitantly with enalapril, the antihypertensive effect of ACE inhibition was attenuated. This effect was thought to result from activation of the sympathetic nervous system by substance P and decreased degradation of neuropeptide Y, resulting in decreased downstream vasodilator effects.In a double-blind, randomized, multicenter, parallel-group study. studied treatment with vildagliptin 50 mg daily and vildagliptin 100

mg daily versus placebo in metformin-treated patients with poor glycemic control for 24 weeks. The results showed that systolic and diastolic blood pressure tended to decrease during Study in each treatment group compared to placebo. The decrease in diastolic blood pressure in patients who received vildagliptin 100 mg daily was significantly greater than in patients who received placebo. Further studies will be needed to elucidate the effects of DPP4 inhibition on hypertension.



Figure 3 (Role of DDP-4i on BP by improving the endothelial function)

The regulatory effects of DPP-4i on blood pressure in the clinical researches and animal e

Drugs	Subjects	Number	Duration	Effects	Date
Saxagliptin	Humans	102	48 w	SBP ↓ and DBP ↓	2018
Sitagliptin	Humans	454	24w	SBP ↓ and DBP ↓	2017
Vildagliptin	Humans	2108	24 w	SBP ↓ and DBP ↓	2016
Sitagliptin	Humans	70	12 w	SBP ↓ and DBP ↓	2016
Sitagliptin/Vildagliptin/Saxagliptin	Humans	25	48w	No effect	2016
Sitagliptin/vildagliptin	Humans	51	12 w	SBP ↓	2016
Vildagliptin	Rats	48	4 w	DBP ↓	2016
Vildagliptin	Rats	17	1 w	SBP ↓	2015
Sitagliptin with enalapril (10 mg/kg)	Rats	12	3 w	SBP ↑ and DBP ↑	2015
Linagliptin	Rats	59	16 w	No effect	2013
Linagliptin	Mice	60	12 w	No effect	2012
Linagliptin	Rats	48	1 w	Mean BP ↓	2012
Saxagliptin	Rats	52	8 w	SBP↓ and DBP↓	2012
Sitagliptin	Rats	16	2 w	SBP↓	2012
Sitagliptin with enalapril (10/5 mg)	Humans	24	3 w	5 mg: BP↑ 10 mg: BP↓	2010

Table 1

Dyslipidemia

Increased circulating levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides are associated with an elevated risk of CVD in type 2 diabetes. fasting or postprandial was independently associated with CVD risk. In a thorough retrospective analysis of patients in the General Electric Centricity database, patients with T2DM were treated with the DPP4 inhibitor sitagliptin from January 1996 to January 2008. These patients showed reductions in levels LDL cholesterol, total cholesterol and triglycerides. Other studies in T2D patients treated with the DPP4 inhibitors sitagliptin and vildagliptin reported decreases in total cholesterol, LDL cholesterol and triglycerides and increases in HDL cholesterol .Additionally, the results of a meta-analysis, designed by Monami et al. to assess the effect of DPP4 inhibitors on lipid levels, showed that the difference in endpoint means from baseline total cholesterol in patients taking DPP4 inhibitors was significantly greater than in patients taking DPP4 inhibitors. controls, meaning that treatment with DPP4 inhibitors was associated with a significant reduction in total cholesterol. In a randomized double-blind crossover study by Boschmann et al. Twenty patients with T2D and a body mass index between 28 and 40 kg/m2 received a 7-day treatment with the selective DPP4 inhibitor vildagliptin or with a placebo. The authors concluded that the effects of DPP4 inhibition on postprandial carbohydrate and lipid metabolism were tissue-specific. Postprandial lipolysis of adipose tissue was associated with an increased rate of systemic postprandial lipid oxidation. They hypothesized that the metabolic response to DPP4 inhibition was due to activation mediated by the sympathetic nervous system GLP1 receptor. Matikainen et al. evaluated the effects of vildagliptin on postprandial lipid and lipoprotein metabolism in patients with DM2, in whom treatment with the DPP4 inhibitor improved the metabolism of triglyceride particles and apolipoprotein B48 after a meal rich in fat. Overall, no significant effect of DPP4 inhibition on circulating lipid concentrations was demonstrated in most clinical studies, as lipid changes were not the primary outcome.

Cardiac ischemic events.

Although it is clear that CV protecting effects of DPP4 inhibition derive from improvement in T2D, a very important risk issue for CV complications, accumulating proof from experimental and clinical studies has steered a control direct GLP1 on the myocardium. In vitro studies have shown that GLP1 upregulates the expression of aldohexose transport macromolecule (GLUT) a pair of and 4, that successively improves internal secretion resistance. GLUT4 expression is markedly reduced in T2D. GLP1 mediates translocation of GLUT4 to the surface of internal organ myocyte to extend glucose uptake. during a recent study, an advert hoc assessment of CV safety in patients with DM2 was performed by pooling data from twenty-five double-blind studies, that randomised patients at baseline to receive sitagliptin or a non-sitagliptin comparator. Included studies were restricted to those locomote in length from twelve to one04 weeks. Major adverse vas events (MACE) were analyzed, together with ischaemic events and CV deaths. Across the entire cohort

analysis, seventy-eight patients according a minimum of 1 MACE-related event, including forty within the sitagliptin cluster and thirty-eight in the unexposed group. during this analysis, the exposure-adjusted incidence rate was 0.65 per one hundred patient-years in the sitagliptin group and 0.74 in the no-pose group; once examination sitagliptin with placebo, the exposure-adjusted incidence rate was 0.80 per one hundred patient-years with sitagliptin and 0.76 with placebo; examination sitagliptin to sulfonylurea, the exposure-adjusted incidence rate was 0.00 per 100 patient-years with sitagliptin and 0.86 with sulfonylurea.

Other Cardiovascular Effects.

Patients with T2DM suffer from obesity-related conditions induced by hypoglycemic agent resistance. epithelial tissue dysfunction has been recognized as associate early development in diabetic tube-shaped structure sickness and could be one in all the key conditions contributive to additional CV morbidity in patients with T2DM. postprandial hyperglycaemia and postprandial hypertriglyceridemia are related to aerophilic stress, endothelial dysfunction, faded fibrinolysis, sympathetic activation, and exaggerated arteriosclerosis coronary plaque burden. A recent study by Matsubara et al. assessed changes in endothelial function in forty Japanese patients with arterial blood vessel disease and diabetes, treated with or while not sitagliptin for six months. beginning mean HbA1c was 7.4%. Patients were assigned (not randomized) to sitagliptin or standard therapy. epithelial tissue perform was assessed by reactive hyperaemia peripheral blood vessel tonometry index (RHI). pulsation blood pressure was considerably lower by seven millimeterHg within the sitagliptin group, whereas systolic BP rose by three mm in the nonsitagliptin group, representing a final treatment distinction of thirteen mmHg between groups. HbA1c wasn't completely different when six months. Patients with sitagliptin experienced a bigger improvement in RHI (endothelial function) relative to the management group, and reductions in serum globulin correlate with improved endothelial function. The authors finished that sitagliptin significantly improved endothelial function and inflammatory state in patients with CAD and uncontrolled T2DM, beyond its hypoglycemic action.

Clinical studies

At present, there are large in progress multicenter clinical trials testing the cardioprotective effects of DPP-4 inhibitors, which, once completed, could give the required confirmative proof fo¬¬r their cardioprotective effects. EXAMINE (Cadiovascular Outcomes Study of Alogliptin in Subjects with T2DM associate degreed ACS) is an ongoing multicenter randomized double-blinded, placebo-controlled superiority trial evaluating CV outcomes following treatment with alogliptin in addition to straightforward care in subjects with T2DM and up to date ACS. The study cluster is compared with standard medical aid while not DPP-4 inhibition. the first outcome live will be time from organization to the primary incidence of a primary internal organ event, defined as a

composite of CV death, nonfatal MI, associate degreed nonfatal stroke. This 5400-patient study completed achievement in Gregorian calendar month 2013 . geographic area (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with T2DM) is a longterm multicenter study that's presently inscribeing and plans to enroll 6,000 patients with a completion date in Gregorian calendar month 2018 . SAVOR-TIMI (Does Saxagliptin scale back the danger of vessel Events once Used Alone or additional to different polygenic disorder Medications?) is an interventional semi-permanent multicenter trial that is currently enrolling and plans to enroll 16,550 patients with a completion date in Apr 2014 . TECOS (Randomized, Placebo-Controlled Clinical Trial to guage Cardiovascular Outcomes Once Treatment with Sitagliptin in Patients With T2DM associate degreed Inadequate Glycaemic Control) may be a clinical trial no inferiority trial designed to assess CV outcomes of semi-permanent treatment with sitagliptin in patients with T2DM (HbA1c of 6.5–8.0%) and a history of CVD. The study cluster are compared with those patients treated with usual normal of care. 1st} outcome live will be time to first confirmed CV event, a composite of CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. Fourteen thousand participants are calculable to be recruited into TECOS, with an estimated study completion date of Gregorian calendar month 2014 . Also, the interim associate degree lysis of results of SITAGRAMI (Safety and effectivity of Sitagliptin and white corpuscle Colony-Stimulating issue in Patients littered with Acute heart muscle Infarction), a clinical trial multicenter trial testing the myocardial create effects once an acute MI of the mix of sitagliptin with G-CSF, are encouraging however have to be compelled to be confirmed with completion of the semi-permanent study.

Conclusion

DPP-4 inhibitors have some CV protecting effects in T2DM in an exceedinglyddition to their medicament actions. further advantages embrace lowering the blood pressure, up the macromolecule profile and therefore the epithelium dysfunction, decreasing the macrophage-mediated inflammatory response, and reducing heart muscle injury. any investigation in a massive cohort is secured to assess the precise mechanisms of CV protective effects of DPP-4 inhibitors.

References

1. S. Simseka and B. E. de Galan, “Cardiovascular protecting properties of incretin-based therapies in kind two diabetes,” Current Opinion in Lipidology, vol. 23, no. 6, pp. 540–547, 2012.
2. --pps-- 2. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of infarction and death from vas causes,” The geographical region Journal of Medicine, vol. 356, no. 24, pp. 2457– 2471, 2007.
3. --pps-- 3. D. J. Drucker, “Dipeptidyl peptidase-4 inhibitors and therefore the treatment of type 2 diabetes,” polygenic disease Care, vol. 30, no. 6, pp. 1335–1343, 2007.
4. 4. E. Mannucci and C. M. Rotella, “Future perspectives on glucagon-like peptide-1, polygenic disease and vas risk,” Nutrition, Metabolism and vas Diseases, vol. 18, no. 9, pp. 639–645, 2008.
5. --pps-- 5. M. Rizzo, A. A. Rizvi, G. A. Spinas, G. B. Rini, and K. Berneis, “Glucose lowering and anti-atherogenic effects of incretinbased therapies: GLP-1 analogues and DPP-4-inhibitors,” skilled Opinion on Investigational Drugs, vol. 18, no. 10, pp. 1495– 1503, 2009.
6. --pps-- 6. pure Cavalot, A. Petrelli, M. Traversa et al., “Postprandial glucose may be a stronger predictor of cardiovascular events than abstinence blood glucose in kind 2 polygenic disease mellitus, significantly in women: lessons from the San Luigi Gonzaga diabetes study,”
7. Journal of Clinical medical specialty and Metabolism, vol. 91, no. 3, pp. 813–819, 2006.
8. --pps-- 7. T. Jose and S. E. Inzucchi, “Cardiovascular effects of the DPP-4 inhibitors,” polygenic disease & tube-shaped structure illness Research, vol. 9, no. 2,
9. pp. 109–116, 2012.
10. 8. D. Dicker, “DPP-4 inhibitors: impact on glycemic management and
11. vas risk factors,” polygenic disease care, vol. 34, pp. S276– S278, 2011.
12. --pps-- 9. R. E. Amori, J. Lau, and A. G. Pittas, “Efficacy and safety of incretin therapy in kind two diabetes: systematic review and metaanalysis,” Journal of the yank Medical Association, vol. 298, no. 2, pp. 194–206, 2007.
13. --pps-- 10. Z. Shah, C. Pineda, T. Kampfrath et al., “Acute DPP-4 inhibition modulates tube-shaped structure tone through GLP-1 freelance pathways,” tube-shaped structure Pharmacology, vol. 55, no. 1–3, pp. 2–9, 2011.
14. --pps-- 11. S. Ogawa, M. Ishiki, K. Nako et al., “Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases beat blood pressure in Japanese hypertensive patients with type 2 diabetes,” The Tohoku Journal of Experimental Medicine, vol. 223, no. 2, pp. 133–135,
15. 2011.
16. --pps-- 12. P. Anagnostis, V. G. Athyros, F. Adamidou et al., “Glucagon-like peptide-1-based therapies and vas disease: wanting on the far side glycaemic control,” Diabetes, avoirdupois and Metabolism, vol. 13, no. 4, pp. 302–312, 2011.

17. 13. G. C. Mistry, A. L. Maes, K. C. Lasseter et al., “Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with delicate to moderate hypertension,” Journal of Clinical Pharmacology, vol. 48, no. 5, pp. 592–598, 2008.
18. --pps-- 14. A. Marney, S. Kunchakarra, L. Byrne, and N. J. Brown, “Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibitionmand angiotensin-converting protein inhibition in humans,” Hypertension, vol. 56, no. 4, pp. 728–733, two010.
19. --pps-- 15. E. Bosi, R. P. Camisasca, C. Collober, E. Rochotte, and A. J. Garber, “Effects of vildagliptin on glucose management over twenty four weeks in patients with kind 2 polygenic disease inadequately controlled with metformin,” polygenic disease Care, vol. 30, no. 4, pp. 890–895, 2007.
20. --pps-- 16. B. G. Nordestgaard, M. Benn, P. Schnohr, and A. TybjærgHansen, “Nonfasting triglycerides and risk of heart muscle infarction, ischaemic heart disease, and death in men and women,” Journal of the yank Medical Association, vol. 298, no. 3, pp. 299–308, 2007.
21. --pps-- 17. E. S. Horton, C. Silberman, K. L. Davis, and R. Berria, “Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with kind two polygenic disease receiving incretin therapies or hypoglycemic agent in a giant cohort database,” polygenic disease Care, vol. 33, no. 8, pp. 1759–1765, 2010
22. 18. M. Monami, C. Lamanna, C. M. Desideri, and E. Mannucci,
23. “DPP-4 inhibitors and lipoids: systematic review and metaanalysis,” Advances in Therapy, vol. 29, no. 1, pp. 14–25, 2012.
24. --pps-- 19. M. Boschmann, S. Engeli, K. Dobberstein et al., “Dipeptidylpeptidase-IV inhibition augments postprandial lipid mobilization and oxidation in kind two diabetic patients,” Journal of Clinical medical specialty and Metabolism, vol. 94, no. 3, pp. 846–852, 2009.
25. --pps-- 20. N. Matikainen, S. Mantt ¨ ari, A. Schweizer et al., “Vildagliptin ¨ medical care reduces postprandial enteric triglyceride-rich compound protein particles in patients with type 2 diabetes,” Diabetologia, vol. 49, no. 9, pp. 2049–2057, 2006.
26. [21] S. G. Chrysant and G. S. Chrysant, “Clinical implications of vas preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors,” yank Journal of Cardiology,
27. --pps-- 21. K. A. B. Davey, P. B. Garlick, A. Warley, and R. Southworth, “Immunogold labeling study of the distribution of GLUT-1 and GLUT-4 in cardiac tissue following stimulation by hypoglycemic agent or ischemia,” yank Journal of Physiology, vol. two92, no. 4, pp. H2009–H2019, 2007.
28. --pps-- 22. S. S. Engel, G. T. Golm, D. Shapiro, M. J. Davies, K. D. Kaufman, and B. J. Goldstein, “Cardiovascular safety of sitagliptin in patients with kind 2 polygenic disease mellitus: a pooled analysis,” vas Diabetology, vol. 12, no. 1, 2013.
29. --pps-- 23. H. R. Patil, pure J. Al Badarin, H. A. Al Shami et al., “Meta-analysis of impact of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type two polygenic disease mellitus,” yank Journal of Cardiology, vol. 110, no. 6, pp. 826–833, 2012.

30. --pps-- 24. P. A. Read, pure Z. Khan, P. M. Heck, S. P. Hoole, and D. P. Dutka, "DPP-4 inhibition by sitagliptin improves the heart muscle response to dobutamine stress and mitigates beautiful in a pilot study of patients with arteria disease," Circulation, vol. 3, no. 2, pp. 195–201, 2010.
31. --pps-- 25. A. Schweizer, S. Dejager, J. E. Foley, A. Couturier, M. LiguerosSaylan, and W. Kothny, "Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large clinical trial kind two polygenic disease population," Diabetes, avoirdupois
32. and Metabolism, vol. 12, no. 6, pp. 485–494, 2010.
33. --pps-- 26. Monami, I. Dicembrini, D. Martelli, and E. Mannucci, "Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of irregular clinical trials," Current Medical analysis and Opinion, vol. 27, supplement 3, pp. 57–64, 2011.
34. --pps-- 27. R. pureederich, J. H. Alexander, F. T. Fiedorek et al., "A systematic assessment of vas outcomes within the saxagliptin drug development program for type 2 diabetes," Postgraduate Medicine, vol. 122, no. 3, pp. 16–27, 2010.
35. --pps-- 28. A. Arakelyan, J. Petrkova, Z. Hermanova, A. Boyajyan, J. Lukl, and M. Petrek, "Serum levels of the MCP-1 chemokine in patients with ischemic stroke and heart muscle infarction," Mediators of Inflammation, vol. two005, no. 3, pp. 175–179, 2005.
36. --pps-- 29. G. P. Fadini, E. Boscaro, M. Albiero et al., "The oral dipeptidyl peptidase-4 substance sitagliptin will increase current epithelial tissue ascendant cells in patients with kind 2 diabetes: potential role of stromal-derived factor-1alpha," polygenic disease Care, vol. 33, no. 7, pp. 1607–1609, 2010.
37. --pps-- 30. G. P. Fadini, C. Agostini, S. Sartore, and A. Avogaro, "Endothelial progenitor cells in the explanation of atherosclerosis," Atherosclerosis, vol. 194, no. 1, pp. 46–54, 2007.
38. --pps-- 31. J. H. O'Keefe, N. M. Gheewala, and J. O. O'Keefe, "Dietary
39. strategies for up post-prandial glucose, lipids, inflammation, and vas health," Journal of the yank faculty of Cardiology, vol. 51, no. 3, pp. 249–255, 2008